Diabetes:DDB1介导的CRY1降解可促进FOXO1所驱动的肝源性糖异生。

2017-10-09 qinqiyun MedSci原创

在糖代谢过程中,通过泛素化调控目的蛋白降解是一个重要的过程。现研究人员发现DDB1-CUL4A泛素E3配体是一种新型代谢调控,可促进FOXO1驱动的肝源性糖异生。

在糖代谢过程中,通过泛素化调控目的蛋白降解是一个重要的过程。现研究人员发现DDB1-CUL4A泛素E3配体是一种新型代谢调控,可促进FOXO1驱动的肝源性糖异生。

特异性地敲除小鼠活体肝细胞的Ddb1会导致肝源性糖异生受损,但同时可保护高脂膳食的小鼠不患高糖血症。

缺乏Ddb1可下调FOXO1蛋白表达,减弱FOXO1驱动的糖异生反应。

研究人员还发现DDB1是通过降解一个已知的DDB1 E3配体的靶点——生理蛋白隐色素1(CRY1)来提高FOXO1蛋白的稳定性。

在Cry1耗尽的情况下,胰岛素不能降低核FOXO1的水平、抑制糖异生基因的表达。在小鼠肝脏Cry1缓慢耗竭则不仅会提高FOXO1蛋白的水平,还可增强肝源性糖异生。

综上所述,DDB1介导的CRY降解是胰岛素调控血糖稳定的一个重要靶点。

原始出处:

Xin Tong,et al.DDB1-Mediated CRY1 Degradation Promotes FOXO1-Driven Gluconeogenesis in Liver.Diabets 2017 Oct; 66(10): 2571-2582. https://doi.org/10.2337/db16-1600

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1664716, encodeId=eccd1664e16c1, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Sun Aug 05 13:44:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901787, encodeId=a6e21901e87c4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri May 04 04:44:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638080, encodeId=20ef163808059, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Feb 25 03:44:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784141, encodeId=4d6a1e8414178, content=<a href='/topic/show?id=4caf5e661f' target=_blank style='color:#2F92EE;'>#Ddb1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5766, encryptionId=4caf5e661f, topicName=Ddb1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Sat Nov 18 09:44:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760243, encodeId=43d91e60243ae, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 05 07:44:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533935, encodeId=08591533935f3, content=<a href='/topic/show?id=132ee62484' target=_blank style='color:#2F92EE;'>#FOXO1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7624, encryptionId=132ee62484, topicName=FOXO1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82812497085, createdName=许安, createdTime=Wed Oct 11 07:44:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251557, encodeId=ed1e25155e72, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b0041939716, createdName=hhh678, createdTime=Mon Oct 09 18:28:32 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1664716, encodeId=eccd1664e16c1, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Sun Aug 05 13:44:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901787, encodeId=a6e21901e87c4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri May 04 04:44:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638080, encodeId=20ef163808059, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Feb 25 03:44:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784141, encodeId=4d6a1e8414178, content=<a href='/topic/show?id=4caf5e661f' target=_blank style='color:#2F92EE;'>#Ddb1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5766, encryptionId=4caf5e661f, topicName=Ddb1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Sat Nov 18 09:44:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760243, encodeId=43d91e60243ae, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 05 07:44:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533935, encodeId=08591533935f3, content=<a href='/topic/show?id=132ee62484' target=_blank style='color:#2F92EE;'>#FOXO1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7624, encryptionId=132ee62484, topicName=FOXO1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82812497085, createdName=许安, createdTime=Wed Oct 11 07:44:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251557, encodeId=ed1e25155e72, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b0041939716, createdName=hhh678, createdTime=Mon Oct 09 18:28:32 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1664716, encodeId=eccd1664e16c1, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Sun Aug 05 13:44:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901787, encodeId=a6e21901e87c4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri May 04 04:44:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638080, encodeId=20ef163808059, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Feb 25 03:44:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784141, encodeId=4d6a1e8414178, content=<a href='/topic/show?id=4caf5e661f' target=_blank style='color:#2F92EE;'>#Ddb1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5766, encryptionId=4caf5e661f, topicName=Ddb1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Sat Nov 18 09:44:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760243, encodeId=43d91e60243ae, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 05 07:44:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533935, encodeId=08591533935f3, content=<a href='/topic/show?id=132ee62484' target=_blank style='color:#2F92EE;'>#FOXO1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7624, encryptionId=132ee62484, topicName=FOXO1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82812497085, createdName=许安, createdTime=Wed Oct 11 07:44:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251557, encodeId=ed1e25155e72, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b0041939716, createdName=hhh678, createdTime=Mon Oct 09 18:28:32 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1664716, encodeId=eccd1664e16c1, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Sun Aug 05 13:44:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901787, encodeId=a6e21901e87c4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri May 04 04:44:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638080, encodeId=20ef163808059, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Feb 25 03:44:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784141, encodeId=4d6a1e8414178, content=<a href='/topic/show?id=4caf5e661f' target=_blank style='color:#2F92EE;'>#Ddb1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5766, encryptionId=4caf5e661f, topicName=Ddb1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Sat Nov 18 09:44:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760243, encodeId=43d91e60243ae, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 05 07:44:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533935, encodeId=08591533935f3, content=<a href='/topic/show?id=132ee62484' target=_blank style='color:#2F92EE;'>#FOXO1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7624, encryptionId=132ee62484, topicName=FOXO1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82812497085, createdName=许安, createdTime=Wed Oct 11 07:44:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251557, encodeId=ed1e25155e72, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b0041939716, createdName=hhh678, createdTime=Mon Oct 09 18:28:32 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
    2017-11-18 zhwj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1664716, encodeId=eccd1664e16c1, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Sun Aug 05 13:44:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901787, encodeId=a6e21901e87c4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri May 04 04:44:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638080, encodeId=20ef163808059, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Feb 25 03:44:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784141, encodeId=4d6a1e8414178, content=<a href='/topic/show?id=4caf5e661f' target=_blank style='color:#2F92EE;'>#Ddb1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5766, encryptionId=4caf5e661f, topicName=Ddb1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Sat Nov 18 09:44:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760243, encodeId=43d91e60243ae, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 05 07:44:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533935, encodeId=08591533935f3, content=<a href='/topic/show?id=132ee62484' target=_blank style='color:#2F92EE;'>#FOXO1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7624, encryptionId=132ee62484, topicName=FOXO1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82812497085, createdName=许安, createdTime=Wed Oct 11 07:44:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251557, encodeId=ed1e25155e72, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b0041939716, createdName=hhh678, createdTime=Mon Oct 09 18:28:32 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1664716, encodeId=eccd1664e16c1, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Sun Aug 05 13:44:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901787, encodeId=a6e21901e87c4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri May 04 04:44:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638080, encodeId=20ef163808059, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Feb 25 03:44:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784141, encodeId=4d6a1e8414178, content=<a href='/topic/show?id=4caf5e661f' target=_blank style='color:#2F92EE;'>#Ddb1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5766, encryptionId=4caf5e661f, topicName=Ddb1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Sat Nov 18 09:44:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760243, encodeId=43d91e60243ae, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 05 07:44:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533935, encodeId=08591533935f3, content=<a href='/topic/show?id=132ee62484' target=_blank style='color:#2F92EE;'>#FOXO1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7624, encryptionId=132ee62484, topicName=FOXO1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82812497085, createdName=许安, createdTime=Wed Oct 11 07:44:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251557, encodeId=ed1e25155e72, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b0041939716, createdName=hhh678, createdTime=Mon Oct 09 18:28:32 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
    2017-10-11 许安
  7. [GetPortalCommentsPageByObjectIdResponse(id=1664716, encodeId=eccd1664e16c1, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Sun Aug 05 13:44:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901787, encodeId=a6e21901e87c4, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri May 04 04:44:00 CST 2018, time=2018-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638080, encodeId=20ef163808059, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Feb 25 03:44:00 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784141, encodeId=4d6a1e8414178, content=<a href='/topic/show?id=4caf5e661f' target=_blank style='color:#2F92EE;'>#Ddb1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5766, encryptionId=4caf5e661f, topicName=Ddb1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5d7367, createdName=zhwj, createdTime=Sat Nov 18 09:44:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760243, encodeId=43d91e60243ae, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 05 07:44:00 CST 2017, time=2017-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533935, encodeId=08591533935f3, content=<a href='/topic/show?id=132ee62484' target=_blank style='color:#2F92EE;'>#FOXO1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7624, encryptionId=132ee62484, topicName=FOXO1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c82812497085, createdName=许安, createdTime=Wed Oct 11 07:44:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=251557, encodeId=ed1e25155e72, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=b0041939716, createdName=hhh678, createdTime=Mon Oct 09 18:28:32 CST 2017, time=2017-10-09, status=1, ipAttribution=)]
    2017-10-09 hhh678

    henhao

    0

相关资讯

Sci Rep:研究初步揭示肝葡萄糖代谢受损导致2型糖尿病发生的机制

肝脏在维持血糖稳态中起着关键的作用,肝葡萄糖代谢受损与2型糖尿病的发生相关。本研究中,研究人员采用RNA测序对比了糖尿病db/db小鼠及正常db/+小鼠肝脏转录组的表达谱,并确定了218个差异表达的基因。在这其中,db/db小鼠肝脏中3个lncRNA表达下调,且H19是下调最为明显的lncRNA。H19的表达与糖酵解和糖异生通路相关基因的表达显著相关,表明肝脏H19的表达水平可直接或间接地调节它们

Nature:缺失重要转录因子FOXO1能让血管“疯长”,可能与肿瘤有关

血管在动物整个生命过程中都扮演着重要角色。血管生长决定着器官是否能够在胚胎发育阶段及时得到营养供应,到了成年阶段,新血管的发育在血管修复和再生过程中发挥重要作用,血管生长过程的紊乱是癌症,糖尿病以及眼部疾病发展的重要因素。

Nature:缺失特殊转录因子或可促进血管生长

血管对生命起着非常重要的作用。血管生长决定着器官是否在胚胎发育期间及时提供营养。在成年期,新血管的生长有助于修复和再生过程。当血管生长受到干扰时,这是癌症、糖尿病和眼疾发展的一个重要的因素。科学家目前已发现血管中细胞层的最内层的生长可以通过新陈代谢来控制。该结果可以作为疾病新治疗方法的基础,血管生长在该疗法中起重要作用。 血管通常被比作水管:管道系统器官为组织供应氧气和营养血液,然而,这种

Front Immunol:FOXO1调节细菌诱导的中性粒细胞的活性

嗜中性粒细胞在先天免疫应答对抗微生物感染中发挥重要作用,在清除细菌感染中尤为重要。我们研究转录因子FOXO1在中性粒细胞对体内和体外牙龈卟啉单胞菌应答的反应中的作用。在这些实验中,将LyzM.Cre + FOXO1 L / L小鼠中谱系特异性FOXO1缺失的影响与匹配的同窝对照进行比较。FOXO1缺失对体内嗜中性粒细胞功能的几个关键方面产生负面影响包括将骨髓(BM)中性粒细胞动员到脉管系统,将嗜中

Blood:FOXO1诱导的致瘤性网络界定AML1-ETO白血病前期程序

FOXO1在人类CD34+细胞表达上调中具有致瘤性,并且可以促进白血病前期向白血病转化。AML1-ETO白血病前体细胞需要FOXO1来激活干细胞的分子过程。